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Langerhans Cell Histiocytosis (LCH) is an orphan disease of clonal dendritic cells which may affect any organ of the
body. Most of the knowledge about the diagnosis and therapy is based on pedriatic studies. Adult LCH patients are
often evaluated by physicians who focus on only the most obviously affected organ without sufficient evaluation of
other systems, resulting in patients being underdiagnosed and/or incompletely staged. Furthermore they may be
treated with pediatric-based therapies which are less effective and sometimes more toxic for adults. The published
literature on adult LCH cases lacks a comprehensive discussion on the differences between pediatric and adult
patients and there are no recommendations for evaluation and comparative therapies. In order to fill this void, a
number of experts in this field cooperated to develop the first recommendations for management of adult patients
with LCH. Key questions were selected according to the clinical relevance focusing on diagnostic work up, therapy,
and follow up. Based on the available literature up to December 2012, recommendations were established, drafts
were commented by the entire group, and redrafted by the executive editor. The quality of evidence of the
recommendations is predominantly attributed to the level of expert opinion. Final agreement was by consensus.
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There are no universally accepted international guide-
lines available for the diagnosis and treatment of adult
LCH patients. The largest number of patients was pub-
lished in a pooled retrospective analysis from several na-
tional registries [1].
Based on the available literature up to December 2012
and personal experience the following recommendations
were established by an international group of academic
clinicians who are recognized experts in the field of his-
tiocytic disorders. Grading of recommendations based
on levels of evidence and agreement between experts is
listed in Table 1.* Correspondence: michael.girschikofsky@elisabethinen.or.at
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distribution, and reproduction in any mediumDue to the diversity of clinical course of LCH, even
recommendations which are established as standard of
care may need to be critically appraised in an individual
case and involvement of a LCH expert should be consid-
ered. A map of experts, reference centers and additional
information about the disease is available on the web-
site of Euro-Histio-Net (http://www.eurohistio.net) and
the Histiocytosis Association (https://www.histio.org/).General consideration
The etiology of LCH is unknown. LCH cells are clonal
(except primary pulmonary LCH) [2,3] and a cancer-
associated mutation (BRAFV600E) was found in more
than half of investigated specimens, indicating that LCH
may be more a neoplastic (not a malignant!) disease than
a reactive disorder, but the pathogenesis is still unclear
[4,5]. Although apparent associations between LCH and
malignant tumors have been recognized, these casesentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Grade of recommendation
Level of evidence Level of agreement between experts
A meta-analyses, high quality
systematic reviews, or
randomized controlled trials
2 general agreement between
all experts
B systematic reviews of case
control or cohort studies
1 discussed recommendation, but no
formal objections between experts
C non-analytic studies:
for example, case reports,
case series, small
retrospective studies
0 divergence of opinion
D expert opinion









(Table 3 and 4; Table 7 in suspected pLCH)
Is therapy required ?
Follow up (Table 9)







Figure 1 Management of Langerhans Cell Histiocytosis
in adults.
Table 2 Diagnostic criteria of LCH
Definitive: Presumptive (or compatible):
Based on clinic-pathological
evidence with microscopic
examination and at least one of the
following immunological staining:
Based only on clinico-radiological
evidence, without biopsy, as
in case of:
• Langerin (CD 207) positivity e.g.: Pulmonary lesions on CT scan
with typical cysts and nodules in a
smoker. (however, biopsy should
be considered in order to reach a
more definitive diagnosis)
• CD1a positivity
• Presence of Birbeck granules
on electronic microscopy
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physiologic relationship remains undefined [6].
The disease may affect any organ or system, more fre-
quently bones, skin, and pituitary gland. Lymph nodes,
liver, spleen, gut, the central nervous system, pituitary,
and the hematopoietic system are less frequently af-
fected. Lungs may be affected simultaneously or con-
secutively with other organs, but isolated pulmonary
LCH (PLCH) occurs frequently in adults and may proceed
to multisystem involvement. PLCH requires a different
management in contrast to multi-organ involvement and
is therefore discussed in a separate section.
Clinical manifestations of LCH vary depending on the
organ or system affected, from self-healing disease to
chronic recurrences. A rapid progressive form, seen in
children, is usually not observed in adults. Langerhans
cell sarcoma (malignant histiocytosis) can occur de novo
or from an antecedent LCH [7]. This paper will not
cover other histiocytic disorders such as Erdheim-
Chester disease (ECD), Rosai-Dorfman disease (RDD) or
malignant histiocytosis. In cases of occurrence of LCH
and ECD or RDD in the same patient, the management
is based on the predominant disease.
Treatment options vary depending on disease extent
and severity at onset. A uniform diagnostic work-up is
necessary (see Figure 1). One of the main problems of
LCH in adults is the variety of potentially involved or-
gans resulting in several physicians being consulted. Fre-
quently only the most obviously affected site is considered
and a complete examination is not done thus missing
other sites of disease.
Diagnosis
The diagnosis of LCH should be based on histologic and
immunophenotypic examination of a lesional biopsy. Nor-
mal Langerhans cells stain positively with CD1a and/or
Langerin [8-10]. Misdiagnoses of LCH have occurred, as
the presence of normal reactive LCs in skin and regional
lymph nodes may be confusing.
The two levels of certainty of LCH diagnosis which are
generally agreed upon are shown in Table 2 [11].Pretreatment clinical evaluation
Complete history
Patients with LCH are often asymptomatic or show only
mild symptoms. The most common symptoms are dys-
pnea, cough, bone pain, an abnormal growth of soft tis-
sue over the affected bone, rash, pruritus, increased
thirst, and lymphadenopathy. Additional signs are fatigue,
generalized weakness, weight loss, night sweats, nausea,
and fever.
A thorough history should be performed including the
questioning about unexplained symptoms in the past
such as “idiopathic” eczema, thyroid disease or diabetes
insipidus, lung cysts or pneumothorax, or bony lesions,
the smoking and family history with special attention to
autoimmune disease. A very small number of familial
cases are reported [12].
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A comprehensive physical examination is necessary. The
skin and visible mucous membranes should be inspected.
Supplemental neurological and/or psychological inves-
tigations are useful in patients presenting with neuro-
myopathy or cognitive impairment.
Laboratory and radiographic evaluation
The laboratory tests to be performed for all patients in-
dependently of affected organs include a complete blood
count, blood chemistry, coagulation studies, thyroid
stimulating hormone (TSH), freeT4 and urine analysis -
see Table 3 (Grade D2).
A skeletal survey, skull series (or low dose whole bone
CT [13]) and chest x-ray (AP and lateral) are the first
radiographic examinations to be done. CT of specific areas
of the skeleton are indicated when mastoid, orbital, scapu-
lar, vertebral, or pelvic lesions are found by plain x-rays.
MRI may detect additional osseous or extraosseous lesions.
A skeletal scintigram (bone scan) alone does not suffice.
Any evidence of a pathological thoracic finding should
be followed up by high-resolution chest CT. Ultrasono-
graphic examination of the abdomen may reveal hepatic
abnormalities. An ultrasound of the neck with attention
to the thyroid gland may be indicated if there are thyroid
nodules or evidence of thyroid dysfunction. A MRI of
head is needed for hypothalamic/pituitary or brain abnor-
malities. PET-(CT) scan may identify lesions missed by
other modalities and documents response to therapy [14].
Further investigations may be indicated based on the
patient's symptoms and the findings of the basic diag-
nostic tests - see Table 3 and 4 (Grade D2).Table 3 Baseline laboratory and radiographic evaluation
Recommendation Grade
Full Blood Count (Hemoglobin, White blood cell and differential
count, Platelet count)
D2
Blood Chemistry (Total protein, Albumin, Bilirubin , ALT (SGPT),
AST (SGOT)
D2
Alkaline phosphatase (AP), gammaglutamyl transpeptidase (γGT)
Creatinine, Electrolytes, CRP (C-reactive Protein)
Erythrocyte Sedimentation Rate (ESR) D1
Coagulation Studies (INR/PT, Fibrinogen) D2
Thyroid Stimulating Hormone (TSH), freeT4 D2
Morning Urine Osmolarity D1
Urine Test Strip D2
Ultrasound (liver, spleen, lymph-nodes, thyroid gland) D2
Chest Radiograph (CXR) D2
Low Dose Whole Body (Bone) CT (if not available: X-Ray
Skeletal/Scull Survey)
D2
Optional: Baseline Head-MRI D2
Optional: PET-CT instead of Ultrasound, CXR and Bone CT D2Definition of organ involvement
Possibly involved organs
After the diagnosis of LCH has been made, involvement
of other organs should be evaluated and defined according
to the clinical, biological or radiological criteria.
Risk organs (bone marrow, liver, spleen, CNS)
Involvement in the hematopoietic system (extremely rare
in adults), spleen, liver or CNS indicates a less favorable
prognosis, with possible mortality if the patient does not
respond to therapy. Although this has never been proven
for adults, retrospective analyses of national registries
and the experts’ experience support the existence of the
above mentioned “risk organs”.
Fever, night-sweats and weight loss combined with
poor performance score might predict the rarely ob-
served aggressive course of LCH in adults comparable to
that of high grade non-Hodgkin lymphoma [15,16].
“Special Sites” and “CNS-Risk” bone involvement
Vertebral lesions with intraspinal or cranofacial bone le-
sions with soft tissue extensions (orbit, mastoid, sphen-
oid or temporal bones) may cause immediate risk to the
patient because of the critical anatomical site and the
hazards of attempting local therapy. Isolated disease in
these “Special Sites” justifies systemic therapy for chil-
dren because of spinal cord compression and the associ-
ation of cranio-facial bone lesions with an increased risk
of developing diabetes insipidus [17]. It is unclear if this
connection might be extrapolated to adults, but most ex-
perts treating LCH patient follow the same guidelines for
their adult patients as with the pediatric cases (Grade D2).
Endocrinologic dysfunction
LCH exhibits a predilection for the hypothalamo-pituitary
(HP) region leading to permanent posterior and/or anter-
ior pituitary hormonal deficiencies in a subset of patients.
Diabetes Insipidus (DI) is the most common disease-
related consequence that can predate the diagnosis or de-
velop anytime during the course of the disease [18,19]. DI
is found in up to 30% of patients [1], but may reach to
40% in patients with multisystem disease or 94% in the
presence of other pituitary deficiencies [18,20]. Polyuria
and polydipsia, and/or structural abnormalities of the HP
region dictate investigations to confirm DI.
Anterior pituitary dysfunction (APD) is found in up to
20% of patients, almost always with DI [18,21]. Although
APD is not invariably associated with abnormal HP im-
aging it is almost always encountered in patients with MS
LCH who have DI and HP pathology on MR imaging [22].
Growth hormone deficiency (GHD) is the most frequent
disease-related APD found in up to 50% of patients with
DI [20]. In adults there are no specific GHD-related symp-
toms that can suggest the diagnosis [23]. Gonadotropin
Table 4 Specific clinical scenarios: recommended additional testing
Recommendation Grade
History of polyuria or polydipsia: D2
• Urine and Plasma osmolality
• Water deprivation test
• MRI of the head
Suspected Other Endocrine Abnormality: D2
• Endocrine assessment (including dynamic tests of the anterior pituitary, MRI of the head)
Bi- or Pancytopenia, Or Persistent Unexplained Single Cytopenia: D2
• Any other cause of cytopenia has to be ruled out according to standard medical practice
• Bone marrow aspirate and trephine biopsy to exclude causes other than LCH
• In case of morphological signs of hemophagocytosis additional tests like serum-ferritin should be performed (criteria of HLH)
Liver Or Spleen Abnormalities: D2
• In case of any unclear sonographically pathology CT, PET-CT, MRI or Scans should be added (the choice is depending on the
sonomorphology – discuss with your radiologist)
• Visuable lesions of the liver should be biopsied if possible
• Other causes of splenomegaly has to be ruled out before it may be assigned to LCH
• ERCP (Endoscopic Retrograde Cholangiopancreatography) or MRCP (Magnetic Resonance Cholangiopancreatography) should be performed
in case of elevated serum cholestasis markers or sonomorphologically dilatated bile ducts. Primary biliary cirrhosis and primary sclerosing
cholangitis have to be ruled out.
Unexplained Chronic Diarrhea, Weight loss, Evidence Of Malabsorption Or Hematochezia D2
• GI-Exploration (Endoscopy with biopsies, capsule endoscopy)
Enlarged Lymph Nodes (LN): D2
• If found by screening ultrasound or physical examination the best suitable LN should be extirpated. A LN needle biopsy should be avoided.
• CT scans or a PET-CT should be performed additionally
Lung Involvement - In case of abnormal Chest X Ray or symptoms/signs suggestive for lung involvement or suspicion of a
pulmonary infection:
D2
• Lung high resolution computed tomography (HR-CT)
• Lung function tests (Spirometry, Diffusing capacity, Oxygen desaturation during exercise (6MWT), blood gases)
• Bronchoalveolar lavage (BAL): > 5% CD1a + cells in BAL fluid may be diagnostic of LCH
• Lung biopsy (if BAL is not diagnostic), ideally Video-assisted thoracoscopic surgery (VATS)
Osseous Disease: D2
• CT +/- MRI should be performed in case of craniofacial or vertebral lesions or signs of additional soft tissue involvement
• Biopsies should be taken from the most suitable region in case of multifocal bone disease
Skin, Oral And Genital Mucosa lesions: D2
• Biopsies should be taken
Aural Discharge Or Suspected Hearing Impairment / Mastoid Involvement: D2
• Formal hearing assessment
• MRI of head
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senting with menstrual disturbances in women and de-
creased libido in men [20]. ACTH deficiency may be
partial or complete and present either with non-specific
symptoms or as acute adrenal insufficiency following
stressful events. TSH deficiency is almost always asso-
ciated with panhypopituitarism and may present with
subtle symptoms or obvious signs of hypothyroidism.
Moderately elevated prolactin levels attributed to pituitarystalk infiltration can cause galactorrhoea in females and
gonadotropin deficiency in all patients. Established endo-
crine deficiencies almost never recover over time, al-
though apparent HP abnormal imaging may often regress
either in response to treatment or as a result of the “nat-
ural course” of the disease [22].
Hypothalamic involvement is less frequent than pituit-
ary involvement and leads to not only pituitary dys-
function, but neuropsychiatric and behavioral disorders,
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and autonomic and metabolic abnormalities. The most
frequent consequence is severe obesity due to increased
appetite. Hypothalamic-related adipsia may seriously com-
plicate the management of DI.
Metabolic abnormalities: One study involving 14 adult
patients and 42 controls has shown that adults with LCH
are at high risk of developing abnormalities of carbohy-
drate metabolism (diabetes mellitus, impaired glucose tol-
erance) and lipid metabolism leading to increased insulin
resistance even in the absence of obesity [24].
Bone metabolism: Adults with LCH may present with
a lower than expected bone mineral density at any age
especially during periods of active disease [25].
Investigation of hormonal deficiencies: Evaluation of
TSH, free T4 and morning urine osmolality is recom-
mended in all patients, further procedures (water depriva-
tion test, plasma osmolality, serum cortisol, insulin like
growth factor I, gonadal steroids and gonadotropin serum
levels) to detect partial DI or anterior pituitary deficiencies
should be performed when clinical symptoms are present
(Grade D2).
Dermatological involvement
Cutaneous LCH can be the great pretender, mimicking a
number of common dermatoses, and may represent the
earliest sign of the disease [26]. The typical scalp lesions
are small translucent papules, 1-2 mm in diameter,
slightly raised and rose-yellow in colour. These lesions
frequently show scaling or crusting, often leading to a
misdiagnosis of seborrheic dermatitis.
Intertriginous involvement in the axillary, inguinal, vul-
var, or anogenital regions with erythema and erosions are
frequently misdiagnosed as eczema, psoriasis, Candida in-
fection, or intertrigo. Generalised skin eruptions can
mimic guttate psoriasis prurigo nodularis or lichen planus.
Gingival involvement is frequently associated with al-
veolar bone involvement and loosening of teeth. Tooth
extraction should be avoided as with treatment they will
embed into the recovering alveolar bone. Nail changes
include paronychia, onycholysis, subungueal hyperkera-
tosis and purpuric striae of the nail bed, suggesting a
wide panel of conditions. Dark-brown striae similar to
those drug-induced are also seen.
Cutaneous LCH has so many different manifestations
that one needs a high level of suspicion and biopsy is es-
sential. Although skin disease may be the primary presenta-
tion, one must investigate for systemic disease (Grade D2).
Gastrointestinal involvement
Gastrointestinal (GI) tract involvement by LCH is rare
and may appear as a solitary colorectal polyp or multiple
granulomatous lesions of the mucous membrane in
the upper and lower GI tract [27]. Patients are oftenasymptomatic. Multiple infiltrations are associated with
abdominal pain, diarrhea, and hypoalbuinemia.
Liver infiltration is characterized sometimes by infiltra-
tion of CD1a+ cells in nodules or by lymphocytes alone
along the portal tracts which may lead to sclerosing
cholangitis. In case of splenomegaly other causes than
LCH primarily have to be ruled out. Pancreatic involve-
ment (mainly tumorous) is extremely rare.
Stratification
Single System LCH (SS-LCH): One organ/system involved
(uni- or multifocal):
➢ Bone: unifocal (single bone) or multifocal (> 1 bone)
➢ Skin
➢ Lymph node
➢ Hypothalamic-pituitary / Central nervous system
➢ Lungs (primary pulmonary LCH)
➢ Other (e.g. thyroid, gut)
Multisystem LCH (MS-LCH): Two or more organs/sys-
tems involved:
➢ With involvement of “Risk Organs” (Hematopoietic
system, spleen, and/or liver, tumorous CNS)
➢ Without involvement of “Risk Organs”
Treatment
Management algorithms (see Figure 1)
Treatment recommendations are based on site and ex-
tension of the disease.
Careful observation, local or “mild systemic” therapy
Bone involvement In case of single system LCH with
unifocal bone involvement of “non-CNS-Risk facial bones”
local therapy and careful observation is recommended.
The modality of treatment depends on location, size, and
symptoms of the disease. Biopsy or curettage is suitable
for histopathologic diagnosis and initiating a healing
process. Complete excision of bone lesions is not indicated
as it may increase the size of the bony defect and the time
to healing or result in permanent skeletal defects. Intra-
lesional injection of steroid may hasten healing. Dosages
of 40 – 160 mg of methylprednisolone have been used
[28] (Grade C2). Radiotherapy is indicated if there is an
impending neurological deficit and a high surgical risk,
e.g. lesion in the odontoid peg or cranial base. For multi-
focal bone LCH and for bone lesions in “special sites”
systemic therapy (see next page under front line treat-
ment) should be given (Grade D2).
Isolated lymph nodes involvement Isolated lymph nodes
involvement is rare but spontaneous regressions have
Table 5 First line systemic therapy
Recommendation Grade
Mild Symptoms, No Risk Organ Involved:
• Methotrexate 20 mg per week p.o/i.v. C1
• Azathioprine 2 mg/kg/d p.o D1
• Thalidomide 100mg/d p.o in skin or soft tissue multifocal
single system LCH
C2
Additionally In Multifocal Bone LCH
• zoledronic acid 4 mg i.v. C2
q 1 (- 6) month (depending on extent and response) C1
Symptomatic, MS-LCH, No Risk Organs involved
• Cytarabine 100 mg/m2 d1-5 q4w i.v. C1
• Etoposide 100 mg/m2 d1-5 q4w i.v. D1
• Vinblastin/Prednisolone (like in pediatric studies) C1
MS-LCH, Risc Organs Involved
• 2-CDA 6 mg/m2 d1-5 q4w s.c./i.v. C2
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and systemic therapy should be omitted [29] (Grade C2).
Skin Involvement Surgical excision should be limited to
solitary lesions, but mutilating surgeries such as hemi-
vulvectomy should not be performed (Grade D2). If the
patient is being treated for multisystem disease the skin
will respond to treatment. In single system skin disease
or in the rare instance where the skin fails to respond fully
to systemic treatment for multisystem disease there are a
number of treatments directed specifically to the skin.
Topical nitrogen mustard: 20% nitrogen mustard applied
to the skin is an effective treatment in children [30]. There
is no published data on treatment in adults and there are
problems with availability in most countries (Grade C1).
Phototherapy: Psoralen plus ultraviolet A (PUVA) [31]
and narrow band ultraviolet (UV) B [32] are effective in
treating cutaneous LCH in individual case reports. It is
difficult to treat patients with intertriginous or scalp in-
volvement and would be contraindicated in penile disease
(Grade C1).
Thalidomide: is a TNF-α antagonist and has been shown
to be effective in treating cutaneous LCH [33] but gives
poor responses in high risk multisystem disease [34]. Dose
of 100mg/day in adults is generally used but toxicity with
peripheral neuropathy must be monitored (Grade C2).
Azathioprine: There are no published reports of the use
of azathioprine (or its metabolite 6-mercaptopurine) in
adults with cutaneous LCH but it is a useful drug in single
system skin as well as multisystem disease [35]. Patients
need to be tested for thiopurine methyl transferase, and if
normal should be treated at a dose of 2mg/kg/day. The
drug takes about 6 weeks to become effective (Grade D1).
Methotrexate: There are published reports on the use
of low dose methotrexate as either single agent treat-
ment or in combination with azathioprine or prednisol-
one. Methotrexate was used successfully at the dosages
of 20mg once weekly [36] (Grade C1).
Involvement of the oral mucous membranes These le-
sions should be treated with “mild systemic” therapy as
described above and extraction of teeth should be avoided
as much as possible. In refractory cases more intensive
systemic treatment is required (see next paragraph)
(Grade D2).
Systemic therapy
Front line treatment Systemic therapy should be con-
sidered in case of the following disease category:
➢ MS-LCH with/without involvement of “risk organs”
➢ SS-LCH with multifocal lesions
➢ SS-LCH with “special site” lesionsThere is no standard first line therapy like in pediatric
LCH. Vinblastine/prednisolone is mentioned in various
chemotherapeutic manuals, but has never been proven
effective for adults in a prospective study. An international
trial failed because of low recruitment rate. Due to lower
risk of neurotoxicity and frequently observed unacceptable
steroid induced side effects some experts prefer mono-
therapy with cladribine, cytarabine or etoposide [35]. In a
retrospective study evaluating 58 adult patients with bone
lesions the authors observed a clear superiority of cyt-
arabine especially to vinblastine/prednisolone but even to
2-CDA in terms of response and toxicity [37]. Intensive
combination chemotherapies (e.g. MACOP-B) are effect-
ive [38] but should be used only in rare cases of an aggres-
sive LCH form [15] (Grade C1).
Until recently, most experts started with 2-CDA in case
of risk organ or tumorous cerebral involvement, but
cytarabine may be a reasonable alternative (Grade C2).
Some investigators have used bisphosphonates for
multifocal bone disease, but patients have to be advised to
the risk of osteonecrosis of the jaw and its prevention [39].
COX-Inhibitors might be more than analgetic drugs and
regression of LCH was observed [40] (Grade C2).
Grade of recommended systemic first line therapy is
listed in Table 5.
Evaluation of response Evaluation is done after 2 to 3
cycles of chemotherapy. If there is disease progression or
reactivation, complete evaluation as recommended in the
previous section has to be performed (Grade D2).
Maintenance therapy Etoposide or 2-CDA are usually
administered up to 6 months. Cytarabine can be given at
low dose monthly up to a year in most patients (6-12 cy-
cles) (Grade D2).
Table 6 Possible indications for the use of radiotherapy
in adults
Recommendation Grade
Isolated “Unresectable” lesion: C2
if a resection would significantly compromise anatomic
function, e.g. odontoid peg, CNS
Recurrent or progressive lesion: C2
In multifocal or multisystem disease only in case of minor
response to standard systemic therapy
Adjuvant treatment following marginal or incomplete
resection: especially in single system bone disease with soft
tissue involvement
C2
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with drugs not used for the first course. In case of further
progression, especially in CNS involvement cytarabine
may be added to 2-CDA (both drugs cross the blood brain
barrier) [41]. Some cases with response to tyrosine kinase
inhibitors (imatinib) have been reported [42,43]. In the
rare case of a most aggressive course of disease hema-
topoietic stem cell transplant has been performed success-
fully as well [44,45]. Clofarabine has been effective for
refractory childhood LCH [46] (Grade C2).
Treatment options in case of reactivation
Reactivations of LCH in adults occur in about 25-38% of
the patients (European national registry data and [37]).
Patients may have further reactivations especially those
with multisystem disease.
Reactivation of single system disease
The choice of treatment options is based on the same
principles as for initial disease.
The options for reactivations of SS-LCH (skin, bone,
other) include
I. Wait and watch approach
II. Local therapy including irradiation (as above)
III.Bisphosphonates for bony disease (as above)
IV.Chemotherapy (as above)
In case of a multisystem reactivation of a SS-LCH, treat-
ment should follow the options for MS-LCH including
systemic therapy (Grade D2).
The efficacy of 2-CDA for single and multisystem reac-
tivated LCH has been proved in a phase II trial [47].
Reactivation after systemic therapy
I. If the reactivation is more than one year after
completion of treatment, re-induction with the prior
chemotherapy may be effective. If however, the
disease is not responsive we suggest discussion with
the reference centre for your country.
II. If reactivation occurs while on treatment, potentially
2nd line strategies as described above, but should be
generally discussed with your reference centre
(Grade D2).
Radiotherapy
In contrast to pediatric recommendations, radiotherapy is
an effective treatment option with acceptable side-effects
for adult patients with LCH in selected situations [48-52].
Most literature data concerning radiotherapy in adult
LCH deal with uni- or multifocal osseous single-system
disease. The local control rates ranged from 75-100%,
complete remission from 79-100%, respectively [53].The dose recommendation for radiotherapy is still con-
troversial and an exact dose-effect relationship has not
been established. There is a wide dose range of applied
total doses from 1,4 Gy up to 45 Gy. In general, a dose
range from 10 to 20 Gy is recommended in adults [50,54])
(Grade C2).
Recommended indications for the use of radiotherapy
in adults with LCH are listened in Table 6.
Treatment and hormone replacement of endocrinopathies
DI should be treated with desmopressin. The timing and
dosage must be individualized. In proven LCH new on-
set DI is a sign of active disease and initiation of sys-
temic treatment is recommended to try to prevent the
development of further hormonal deficiencies although
existing ones usually do not resolve [55]. Adequate re-
placement of hormonal deficiencies should be initiated
as soon the diagnosis is made (Grade D2).
Central nervous system involvement
Tumorous lesions
These lesions are most frequently observed in the
hypothalamic-pituitary region. The tumor size ranges
from discrete thickening of the pituitary stalk to larger tu-
mors. Parenchymal, meningeal or choroid plexus lesions
occur less frequently [56].
In addition to hormone replacement isolated cerebral
tumors should be treated with irradiation or chemother-
apy and pituitary/hypothalamic lesions with chemother-
apy. Multifocal brain lesions or single brain lesions with
multi system disease need to be treated with chemother-
apy. The most suitable drugs are Cladribine or Cytarabine
as described above (Grade C2).
Neurodegerative LCH
Non-tumorous MRI findings of the cerebellum, and/or
brain stem are histopathologically different than the typ-
ical LCH mass lesions. The neurodegenerative lesions
lack CD1a+ histiocytes and have infiltrating CD8+ lym-
phocytes [55]. Some of these patients show no symptoms,
others have clinical signs ranging from subtile tremor,
Table 7 Diagnostic recommendations in pLCH
Recommendation Grade
Confirm definitive diagnosis
• in all patients before start of systemic therapy D2
• prefer lung biopsy D2
• HRCT is required in all patients D2
Exclude Existence Of Multi System LCH D2
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ataxia, behavioral disturbances and severe psychiatric
disease.
Retinoic acid and intravenous immunoglobulin may sta-
bilize such patients [57,58]. Improvement with infliximab
has been observed in one case [59]. Cytarabine with or
without Vincristine provided improvement in 5/8 patients
of which 4/8 remained stable over more than 7 years of
follow-up and one relapsed but is improved after treat-
ment with intravenous Methotrexate. Patients who
responded to Cytarabine/Vincristine had symptoms for
less than 18 months before starting treatment [60,61].
Thus early onset of Cytarabine is recommended as first
line therapy, but for any case of neurodegenerative LCH




The incidence of pulmonary LCH (PLCH) is unknown.
Reports provided by histopathological studies and inter-
stitial lung diseases registries revealed about 5% of PLCH
in this population [62]. Data from a Japanese survey
show an estimated prevalence of 0.07-0.27/100000 popu-
lation in females and males, respectively [63]. The preva-
lence may be underestimated.
PLCH affects mainly young, predominantly smoking
(> 90%) adults with a peak at 20-40 years of age and a
slight predominance of women. It is unknown if there
are any racial differences in this disease [62].
Clinical features
Patients with PLCH often present with a non-productive
cough or dyspnoea, chest pain, associated non-specific
symptoms like fatigue, weight loss, night sweats and
fever may be observed [62,64]. About 20% of patients
with PLCH are initially asymptomatic and an equal per-
centage of patients present with acute symptoms of a
pneumothorax.
It is important to exclude the existence of multi system
LCH. Thus, a thorough history, comprehensive physical
examination, and baseline radiographic, blood and urine
tests should be performed in any patient presenting with
PLCH to avoid undertreatment. (see Table 3 and 4).
Diagnosis
X-Ray of the chest shows a reticulo-micronodular pat-
tern. In more advanced cases cysts may be visible within
the infiltrates symmetrically in both lungs, but predom-
inating in the middle and upper lung fields and sparing
the costophrenic angles [62].
High resolution CT (HRCT) is the most important
visualizing tool for PLCH [62]. The typical HRCT pat-
tern is of small nodules, cavitated nodules (both mayresolve), and thick- and finally thin-walled cysts. As the
disease evolves, cystic lesions become a predominant
finding.
Pulmonary lung function tests most frequently show
reduced diffusing capacity of the lung for carbon mon-
oxide (DLCO), 70–90% of the patients. Lung volumes
are impaired in a majority of patients with decreased
vital capacity and air trapping (elevated residual volume).
Total lung capacity is within normal values in most cases.
An obstructive pattern is observed in a sizeable proportion
of patients, particularly in advanced disease. Rarely a re-
strictive component may appear [65]. A predominantly
nodular pattern suggestive of active inflammatory disease
can have only moderate functional consequences [65].
Bronchoalveolar lavage (BAL) often shows high alveo-
lar macrophage counts, reflective of smoking. Infection
should be systematically ruled out. BAL yielding more
than 5% CD1-positive cells has previously reported to
support the diagnosis of pulmonary LCH [66]. While
this has a high specificity, BAL results lack sensitivity.
Bronchial biopsies are not helpful in the diagnosis of
PLCH but are useful in ruling out other diagnoses in pa-
tients with atypical manifestations. The diagnostic method
of choice is therefore videothoracoscopic lung biopsy after
HRCT evaluation (see Table 7). In asympto-matic patients
with a typical HRCT pattern and a macrophage alveolitis
by BAL, for whom no systemic therapy is required, a pre-
sumptive diagnosis may be acceptable with a close follow-
up. In patients with extensive cystic lesions, the risk of
invasive procedures has to be balanced with the need for
a definitive diagnosis (Grade D2).
Treatment and prognosis
The natural history of adults with PLCH is widely vari-
able and mostly unpredictable in the individual patient.
About 40-50% of patients with PLCH experience a favor-
able outcome and partial or complete clearance of the
radiological abnormalities occurs with or without therapy.
Serial lung function tests are essential for following pa-
tients with PLCH. In a recent retrospective multicenter
study, lung function (mainly DLCO and FEV1) deterio-
rated in approximately 60% of the patients [65]. An iso-
lated decline of DLCO in symptomatic patients should
prompt a search for pulmonary hypertension by echo-
cardiography and in case of increased systolic pulmonary
Table 8 Therapeutic recommendations in pLCH
Recommendation Grade
First step is smoking cessation in all patients C2
Watchful waiting in a- or minor symptomatic patients C2
Systemic steroid therapy in symptomatic patients C2
Chemotherapy (e.g. 2-CDA) in progressive disease C2
Consider lung transplantation in case of severe respiratory
failure or major pulmonary hypertension
C2
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catheterization [67].
Based on the epidemiologic data smoking cessation is
essential. Patients with a stable disease despite ongoing
smoking should be told about all other known medical
reasons for ceasing smoking and enrollment in a support
group may be valuable [62,64].
There are no study-based data supporting cortisone
therapy for pulmonary LCH. Any possible therapeutic
benefit for symptomatic patients should, therefore, be
carefully weighed against the potential undesired effects
of this form of treatment, because spontaneous remis-
sions do occur. If smoking cessation failed and treatment
is required systemic steroid therapy (usually 1mg/kg/dayTable 9 Recommendations for follow-up
Test
SS-LCH And No Disease Activity
History (especially of thirst, polyuria, cough, dyspnea, bone pain, skin change
neurological symptoms)
Clinical assessment, blood count and blood chemistry (as described in baseli
diagnostics), ultrasound
Chest XR
After MS-LCH And With No Disease Activity
History (especially of thirst, polyuria, cough, dyspnea, bone pain, skin change
neurological symptoms)




Patients With Active Disease
Diagnostic procedures are depending on the site of organ involvement
Patients With pLCH
History (in case of non-pulmonary symptoms: look for MS LCH, see Table 4)
Diagnostic procedures are depending on symptoms und course of PLCH
(baseline: Chest X-ray, lung function (+DCLO)for one month, followed by tapering dosages over months)
may be given in patients with the nodular form of pul-
monary LCH [62,64].
Lower respiratory tract infection is a common cause of
deterioration of PLCH and should lead to prompt treat-
ment. Annual vaccination against influenza as well as
anti-pneumococcal is recommended for patients with
impaired lung function.
Progressive PLCH despite steroid therapy may be
treated with 2-CDA [68,69]. A randomized controlled
trial evaluating the effectiveness and tolerance of 2-CDA
in this subgroup of patients is ongoing.
Pneumothorax requires drainage and pleurodesis should
be considered in case of recurrence [70]. Lung transplant-
ation (LT) may represent a therapeutic option in case of
advanced PLCH (severe respiratory failure or major pul-
monary hypertension). Recurrence of LCH after transplata-
tion occurs in 20% without impact on the survival rate [71].
Grades of recommendations for therapy in pLCH are
listed in Table 8.
Pregnancy
There are only a few reports about pregnancy and LCH
with worsening to no change of clinical symptoms, butFrequency Grade
s, • Every clinic visit D2
ne • End of therapy D2
• every 6 month (for the next 2 years)
• then once a year (for at least 3 years)
• annually (for at least 3 years) D2
s, • Every clinic visit D2
ne • End of therapy D2
• every 3 month (for the next 2 years)
• every 6 month (for the next 3 years)
• then once a year (for at least 5 years)
• annually (for at least 3 years) D2
• Once a year (until end of routinely follow up) D2
Frequency is depending on rates
and velocity of recurrences
D2
• Every clinic visit D2
• End of therapy D2
• every 6 month (for the next 2 years)
• then once a year (for at least 5 years)
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ly related to diabetes insipidus. It is unclear if worsening
or onset of DI during pregnancy is really caused by LCH.
This may also be observed in women not suffering from
a histiocytic disorder and is caused by an accelerated
degradation of vasopressin through placental enzyme
vasopressinase [72].
It is unpredictable if and in which way pregnancy may
influence the course of LCH. The scant literature sug-
gests there is no adverse impact of LCH on pregnancy
or birth, with exception of need for cesarean section in
selected cases [73,74] (Grade C2).
Follow up
LCH may reactivate and lead to chronic local symptoms
or induce organ dysfunction. Rarely LCH is associated
with malignant tumors. Therefore, follow-up investiga-
tions of disease and monitoring of functional impair-
ments are necessary.
Restaging every 2-3 months is standard. Follow-up in-
tervals depend on the primary extent and activity of dis-
ease within 3 to 12 months (see Table 9). In case of
affirmed reactivation, clinical evaluation should include
all investigations listed above (Grade D2).
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